

1 **Research Letter: Proteome-wide Mendelian randomization identifies OLFM1 as**
2 **a potential mediator of the risk effect of myxoedema on haemorrhoidal disease**

3 Shifang Li^{#*}, Meijiao Gong[#]

4 Laboratory of Immunology and Vaccinology, FARAH, ULiège, Liège 4000, Belgium.

5 [#]Shifang Li and Meijiao Gong contributed equally to this work

6 *Correspondence:

7 Shifang Li, fruceslee@gmail.com

8 Laboratory of Immunology and Vaccinology, FARAH, ULiège, Liège 4000, Belgium

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24 **Abstract**

25 Human haemorrhoidal disease (HEM) is a common anorectal pathology. Being one of
26 the diseases that affect a wide range of people, the etiology of HEM, as well as its
27 molecular mechanism, remains largely unclear. In this study, we applied a two-sample
28 bi-direction Mendelian randomization (MR) analysis to estimate the causal effects of
29 4677 plasma proteins on HEM outcomes and investigated the mediating impacts of
30 plasma proteins on HEM risk factors to uncover potential HEM treatment targets by
31 integrating GWASs statistics of HEM and plasma protein levels. Following MR
32 analysis, our study identified 13 probable causal proteins associated with HEM.
33 Particularly, genetically predicted OLFM1 levels were linked to an increased risk of
34 HEM. In addition, it was discovered that a genetically greater risk of myxoedema,
35 diverticular disease, and ulcerative colitis was linked to an elevated risk of HEM
36 ($FDR < 0.05$). However, there was no evidence that dorsalgia, hernia, and ankylosing
37 spondylitis were causally associated with HEM. Interestingly, a higher risk of
38 myxoedema was associated with higher genetically predicted OLFM1 levels. Finally,
39 mediation analysis suggested that the effect of myxoedema on HEM via OLFM1
40 might explain 32.8% of the mediation effect. Overall, this study identified some
41 causal associations of circulating proteins and risk factors with HEM by integrating
42 the largest-to-date plasma proteome and GWASs of HEM. The findings could provide
43 further insight into understanding biological mechanisms for HEM.

44 **Keywords**

45 Haemorrhoidal disease, Mendelian randomization, OLFM1, myxoedema

46 Human haemorrhoidal disease (HEM) is a common anorectal disorders.
47 Recently, Zhang *et al.* reported the first and largest genome-wide association study
48 (GWAS) with haemorrhoidal disease (HEM), and these data offered us a resource for
49 understanding the genetic risk factors for HEM.¹ However, being one of the diseases
50 that affect a wide range of people, the etiology of HEM, as well as its molecular
51 mechanism, remains primarily unclear.² In addition, identification of genes with
52 therapeutic effects needs to be conducted. Here, we applied a two-sample bi-direction
53 Mendelian randomization (MR) analysis to estimate the causal effects of 4677 plasma
54 proteins on HEM outcomes and investigated the mediating impacts of plasma proteins
55 on HEM risk factors to uncover potential HEM treatment targets by integrating
56 GWASs statistics of HEM and plasma protein levels (**Figure 1**).

57 As stated in the **Supplementary Methods**, we used 4677 protein quantitative
58 trait loci (pQTL) of proteins as instrumental variables for exposure and HEM as the
59 outcome to estimate the causal effect of plasma protein levels on HEM in a proteome-
60 wide context using MR analysis.³⁻⁶ Following a stringent filtering approach, our study
61 identified 13 probable causal proteins ($FDR < 0.05$), including 4 negative and 9
62 positive associations (**Figure 2A**). MR analysis, for example, revealed that genetically
63 predicted OLFM1 levels were linked to an increased risk of HEM ($p = 1.27 \times 10^{-6}$)
64 (**Figure 2B**). Notably, only two (GUK1 and IL1RL2) of the 13 causative associations
65 with HEM have been proposed to be driven by *cis*-regulatory variations, with the
66 remaining significant associations assumed to be driven by *trans*-SNPs.

67 Following that, we attempted to identify causal risk factors for HEM. 6 clinical

68 traits that genetically correlated with HEM were selected (**Supplementary Methods**),
69 with instrumental variables generated from GWAS results confined to European
70 populations. It was discovered that a genetically greater risk of myxoedema,
71 diverticular disease, and ulcerative colitis was linked to an elevated risk of HEM
72 ($FDR < 0.05$) (**Figure 2C**). Although genetic correlations with HEM were reported,¹
73 there was no evidence that dorsalgia, hernia, and ankylosing spondylitis were causally
74 associated ($p > 0.05$). Subsequently, MR analyses were further conducted using
75 myxoedema genetic data from the Neale lab Consortium to assess whether this causal
76 estimation could be repeated. A consistent causal effect of myxoedema on the risk of
77 HEM utilizing these MR analyses was found ($p < 0.05$) (**Figure 2D**).

78 In order to identify the protein related to HEM risk factors, we conducted MR
79 analysis again on 13 plasma proteins impacting HEM with 3 risk factors. After
80 adjusting for multiple testing, we discovered that only myxoedema exhibited a
81 substantial causal association with OLFM1 (**Figure 2E**). Particularly, a higher risk of
82 myxoedema was associated with higher genetically predicted OLFM1 levels ($p = 9.5e-$
83 06) and this causal effect could also be replicated when using the genetic data of
84 myxoedema from the Neale lab Consortium ($p = 4.9e-05$) (**Figure 2E**). Notably, the
85 direction of action of myxoedema with OLFM1 was consistent with the link of
86 proteins with HEM, suggesting that these proteins may be potential mediators of the
87 myxoedema-HEM association. To study the indirect effects of protein-mediated risk
88 variables on HEM outcomes further, a mediation analysis using two-step MR and
89 coefficient product methods was performed to understand the extent to which plasma

90 OLFM1 levels mediate the association between myxoedema and HEM (**Figure 2F**). It
91 was found that nearly one-third (32.8%) of myxoedema-induced effects were
92 mediated by OLFM1.

93 Overall, this study identified some causal associations of circulating proteins and
94 risk factors with HEM by integrating the largest-to-date plasma proteome and GWAS
95 of HEM. OLFM1 was found to be a potential mediator of the risk effect of
96 myxoedema on HEM. The findings could provide further insight into developing
97 potential targets for HEM.

98 **Competing interests**

99 None declared.

100 **Contributors**

101 SF was involved in conceptualization. SF and MJ were involved in the formal
102 analysis. SF was involved in writing, reviewing, and editing.

103 **Acknowledgments**

104 The authors would like to thank all of the researchers who contributed to the GWAS
105 datasets used in this study for making them available for research purposes.

106 **References**

107 1 Zheng T, Ellinghaus D, Juzenas S, *et al.* Genome-wide analysis of 944 133
108 individuals provides insights into the etiology of haemorrhoidal disease. *Gut*
109 2021;70:1538-49.

110 2 EAM Festen & RK Weersma. Large-scale genetic analyses in an understudied
111 disease: haemorrhoidal disease. *Gut* 2021;70:1429-1430.

112 3 Zheng J, Haberland V, Baird D, *et al.* Phenome-wide Mendelian randomization

113 mapping the influence of the plasma proteome on complex diseases. *Nat Genet*
114 2020;52:1122-31.

115 4 Chen L, Peters JE, Prins B, *et al.* Systematic Mendelian randomization using the
116 human plasma proteome to discover potential therapeutic targets for stroke. *Nat*
117 *Commun* 2022;13:1-14.

118 5 Yoshiji S, Butler-Laporte G, Lu T, *et al.* Proteome-wide Mendelian randomization
119 implicates nephronectin as an actionable mediator of the effect of obesity on COVID-
120 19 severity. *Nat Metab* 2023;5:248-64.

121 6 Chen J, Xu F, Ruan X, Sun J, *et al.* Therapeutic targets for inflammatory bowel
122 disease: proteome-wide Mendelian randomization and colocalization analyses.
123 *EBioMedicine* 2023;89:104494.

124 **Figure Legends**

125 **Figure 1 An overview of MR in this study.** A two-step MR approach was used to
126 determine the mediate effect of myxoedema on HEM via plasma protein: First, we
127 employ MR to quantify the effect of 4677 plasma protein levels on HEM, which
128 provided 13 plasma proteins linked with HEM after a strict filtering approach (step 1
129 MR). Subsequently, we used MR to quantify the effect of the risk factors on HEM
130 outcomes (step 2 MR). The effect of the risk variables on HEM-related proteins was
131 next investigated using MR (step 3 MR). Finally, mediation analysis was carried out
132 to assess the proportion mediated by plasma protein levels for the effect of risk factors
133 on HEM outcomes (step 4 mediation analysis). In steps 2 and 3, the effect of causality
134 was validated using GWAS of myxoedema from the Neale lab Consortium. IVW,

135 inverse variance weighted; LOOA, leave-one-out analysis; FDR, false discovery rate;
136 HEM, haemorrhoidal disease; IV, instrumental variable; MR, Mendelian
137 randomization; UC, ulcerative colitis; FDR, false discovery rate.

138 **Figure 2 Mendelian randomization results.** (A) The effect of plasma protein levels
139 on HEM. (Left) Volcano plot indicating the effect of plasma protein on HEM using
140 MR analysis using the inverse variance weighted approach. Red represents the
141 positive association of plasma proteins with a high risk of HEM, whereas blue
142 represents the negative correlation of plasma proteins with HEM. (Right) Manhattan
143 plot depicting the distribution of plasma protein linked with HEM across
144 chromosomes. (C) Forest plots showing the causal effect of chosen risk factors on
145 HEM. (D) Forest plots illustrating the causative effect of myxoedema on HEM using
146 myxoedema GWAS from the Neale lab Consortium. (E) Dot plots indicated the odd
147 ratio (OR) estimates and 95% confidence interval (CI) values of the causal effects of
148 myxoedema on OLFM1, calculated using myxoedema GWAS from the Medical
149 Research Council-Integrative Epidemiology Unit (MRC-IEU) consortium (Left) and
150 the Neale lab Consortium (Right), respectively. (F) Assess the effect of myxoedema
151 on HEM via OLFM1 by mediation analysis. To estimate the mediate effect of
152 OLFM1, the product of coefficients method was used, where $\beta_{\text{myxoedema-to-OLFM1}}$ is the
153 effect of myxoedema on OLFM1, $\beta_{\text{OLFM1-to-HEM}}$ is the effect of OLFM1 on HEM, and
154 $\beta_{\text{myxoedema-to-HEM}}$ is the total effect of myxoedema on HEM. The x-axis for B and E
155 reflects SNP exposure effects, while the y-axis shows SNP outcome effects. HEM,
156 haemorrhoidal disease.

157 **Supplementary Methods** The statistics method used in the study.

158 **Supplementary Tables1** The significant MR summary statistics obtained in this

159 study.

1. Identification of candidate HEM-related proteins

GWAS of 4677 plasma proteins
[35,559 individuals]

Selection of IVs
[pQTLs, $p \leq 5e-08$, $r^2 < 0.001$]

MR: Proteome → HEM outcome

Filter out

13 HEM-associated proteins



2. Identify HEM risk factors

Selected 6 clinical traits

Selection of IVs
[Exclude MHC region, $p \leq 5e-08$, $r^2 < 0.001$]

MR: risk factors → HEM outcome

Filter out

3 risk factors are likely causal for HEM:
Myxoedema, Diverticular disease, UC



3. Identify HEM risk factors associated proteins

Exposure:
3 risk factors

Outcome:
13 proteins

MR: Causal risk factors → Proteome

Filter out


Myxoedema associated with OLFM1



4. Perform mediation analysis


Risk factor associated with HEM
outcome and protein

Mediation analysis: Two-step MR



- 1. Pleiotropy, $p < 0.05$
- 2. IVW random, $p > 0.05$
- 3. Inverse MR, $p < 0.05$
- 4. LOOA, $p > 0.05$
- 5. FDR, $p > 0.05$
- 6. IVs < 3

- 1. Pleiotropy, $p < 0.05$
- 2. IVW random, $p > 0.05$
- 3. Inverse MR, $p < 0.05$
- 4. LOOA, $p > 0.05$
- 5. FDR, $p > 0.05$
- 6. IVs < 3



Supplementary Methods

GWASs of haemorrhoidal disease and risk factors

We used recently published large-scale genome-wide associations (GWASs) for haemorrhoidal disease (HEM).¹ This GWAS summary statistics were derived from 944,133 European ancestry individuals (Ncase = 218,920 and Ncontrol = 725,213) from 5 cohorts and downloaded from the GWAS Catalog (<https://www.ebi.ac.uk/gwas/>, access ID: EFO_0009552). Diverticular disease of the intestine, ankylosing spondylitis (AS), ulcerative colitis (US), dorsalgia, and hernia were evaluated as potential causal risk factors associated with HEM in order to determine the probable causal risk factors. All GWASs for the six risk factors were obtained from the ieu open gwas project (<https://gwas.mrcieu.ac.uk/datasets/>). The summary statistics of the large GWAS (14,357 cases and 182,423 controls) were used for diverticular disease of the intestine (access ID: finn-b-K11_DIVERTIC). The GWAS for AS (access ID: finn-b-M13_ANKYLOSPON) have a sample size of 1,462 cases and 164,682 controls. The GWAS for myxoedema (access ID: ukb-b-19732) have a sample size of 22,687 cases and 440,246 controls. In the GWAS for the US (access ID: finn-b-K11_ULCER), a sample size of 4,320 cases and 210,300 controls were reported. The GWAS for dorsalgia (access ID: finn-b-M13_DORSALGIA) included 193467 individuals, with 28,785 cases and 164,682 controls. A total of 218792 individuals were reported with GWAS of hernia (access ID: finn-b-K11_HERNIA), including 28,235 cases and 190,557 controls. The GWAS for myxoedema (access ID: ukb-a-77), which included 337,159 individuals, including

16,376 cases and 320,783 controls, were utilized to validate MR results.

Plasma protein quantitative trait loci (pQTL) data

To conduct Proteome-wide Mendelian randomization (MR), we first obtained genetic instrumental variables using the protein quantitative trait loci (pQTL) data generated by Ferkingstad *et al.*² The largest-to-date pQTL analysis on plasma proteome (a total of 4907 proteins) in 35,559 Icelanders was performed in their study, and an amount of 18,084 pQTL associations between genetic variation and protein levels in plasma were identified. A total of 4667 pQTLs were successfully downloaded from the deCODE study (access date 03/06/2023) using aria2c.³ In the following analysis, *cis*- and *trans*-pQTLs from each corresponding GWAS were employed as genetic instruments for each protein.

Mendelian randomization analysis

MR analysis is an analytical method that uses genetic variation as an instrumental variable (IV) to estimate causal effects. It overcomes the limitations of measurement error and confounding factors that are common in observational studies and is widely used to assess causal relationships.⁴ In this study, the TwoSampleMR package (v0.5.6, <https://mrcieu.github.io/TwoSampleMR/>) was used for MR analysis.⁵ The instrumental variables that determined the exposure in each MR study were specified as genome-wide significant ($p \leq 5e-08$) and independent SNPs. SNPs in the human major histocompatibility complex (MHC) region at chromosome 6: 28,477,797-33,448,354 (GRCh37) were excluded from the analysis of inferring the causal effect of risk factors on protein levels and HEM due to its complex linkage

disequilibrium (LD) structure. Using the 1000 Genomes Project European reference panel and an LD threshold of $r^2 > 0.001$ with a clumping window of 10,000 kb, PLINK v.1.9 (<http://pngu.mgh.harvard.edu/purcell/plink/>) was employed to derive instrumental variables.⁶⁻⁷ F-statistics were used to determine the strength of each SNP's association with exposure, and F-statistics of more than 10 were considered strong. The inverse-variance weighted (IVW) approach with a fixed effects model was employed for the main MR analysis to assess the causal influence of exposure on outcome. In addition, four additional MR methods (weighted median, simple mode, weighted mode, and MR-Egger method) were used to assess the reliability of the primary results. For exposures with multiple IVs, we additionally investigated heterogeneity across variant-level MR estimations with the "mr_heterogeneity()" function in the TwoSampleMR package (Cochrane's Q test). In addition, a pleiotropy test was performed using MR Egger analysis to determine whether there is horizontal pleiotropy among IVs.

Finally, in the event there are more than two IVs in exposure, a leave-one-out analysis is performed, and the MR findings of the remaining IVs are calculated by deleting the IVs one by one to ensure the robustness of the MR data. To acquire robust evidence for the casual estimation, MR findings that meet all of the following criteria were chosen: (1) no pleiotropy was found using MR-Egger regression ($p > 0.05$); (2) consistent results were obtained using the IVW method and weight median model ($p < 0.05$); (3) IVW random effect model $p < 0.05$; (4) leave-one-out analysis $p < 0.05$ after removing outliers; and (5) reverse MR $p > 0.05$; (6) more than 2 IVs were used in

MR analysis. The same procedure as mentioned above was utilized to explore the causal effect of the given exposure and associated outcome in the reverse MR analysis. For multiple testing, the *p*-values were adjusted using the Benjamini-Hochberg (BH) method. To determine whether the significant relationships found in our analysis were caused by *cis*-regulatory variations, we selected *cis*-SNPs (SNPs located within $\pm 5,000$ kb window from the gene body of the target gene) from all important plasma proteins and carried out Mendelian randomization studies with the HEM GWASs using IVs.

Mediation analysis

Using two-step MR, a mediation analysis was performed to assess the proportion of the effect of myxoedema on HEM that was mediated by OLFM1. In brief, the effect of myxoedema on OLFM1 was first assessed, then multiplied by the effect of OLFM1 on HEM. Following that, the proportion of the entire effect of myxoedema on HEM mediated by OLFM1 was determined by dividing the OLFM1-mediated effect (OLFM1-to-HEM) by the whole effect (myxoedema-to-HEM), as previously stated.⁸⁻¹⁰

References

- 1 Zheng T, Ellinghaus D, Juzenas S, *et al.* Genome-wide analysis of 944 133 individuals provides insights into the etiology of haemorrhoidal disease. *Gut* 2021;70:1538-49.
- 2 Ferkingstad E, Sulem P, Atlason BA, *et al.* Large-scale integration of the plasma proteome with genetics and disease. *Nat Genet* 2021;53:1712-21.

- 3 Aria2c Multi-source Download Utility. Available: <http://aria2.sourceforge.net/>
- 4 Skrivankova VW, Richmond RC, Woolf BAR, *et al.* Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): Explanation and elaboration. *BMJ* 2021;375. doi:10.1136/bmj.n2233
- 5 Hemani G, Zheng J, Elsworth B, *et al.* The MR-base platform supports systematic causal inference across the human phenome. *Elife* 2018;7:1-29.
- 6 Auton A, Abecasis GR, Altshuler DM, *et al.* A global reference for human genetic variation. *Nature* 2015;526:68-74.
- 7 Purcell S, Neale B, Todd-Brown K, *et al.* PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007;81:559-75.
- 8 Yoshiji S, Butler-Laporte G, Lu T, *et al.* Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. *Nat Metab* 2023;5:248-64.
- 9 Burgess S, Daniel RM, Butterworth AS, *et al.* Network Mendelian randomization: Using genetic variants as instrumental variables to investigate mediation in causal pathways. *Int J Epidemiol* 2015;44:484-95.
- 10 Carter AR, Gill D, Davies NM, *et al.* Understanding the consequences of education inequality on cardiovascular disease: Mendelian randomisation study. *BMJ* 2019;365:1-12.